IRF1 and melanoma: In melanomas that were deficient in both IRF1+IRF2, IFN treatment failed to restore the MHC I pathway and reverse the resistance to CPI, indicating that the beneficial effects of the IFN treatment were mediated through the substitutive activity of the transcription factor IRF1.